Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2022 | $25.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. initiated coverage of BriaCell Therapeutics with a rating of Buy and set a new price target of $25.00
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)
FWP - BriaCell Therapeutics Corp. (0001610820) (Subject)
S-1 - BriaCell Therapeutics Corp. (0001610820) (Filer)
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is surging toward $594.3 billion by 2035 as high-tech immunotherapies begin to replace traditional chemotherapy[1]. With response rates now exceeding 90% in some previously untreatable blood cancers, these platforms are demonstrating a unique ability to reactivate a patient's own immune system to fight back[2]. This fundamental shift toward "reprogramming" the body's defenses drives the investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), BriaCell Therapeutics Corp. (NASDAQ:BCTX) (TSX:BCT), Greenwich LifeSciences, Inc. (NASDAQ:GLSI), C
BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS®) Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to support biomarkers to identify patients who benefit from treatment with BriaCell's regimenMaturing Phase 2 study data continues to support meaningful clinical benefit of the Bria-IMT regimen with outstanding long-term survival No toxicity related discontinuations in Phase 3 PHILADELPHIA and VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel im
Over 230 patients screened and over 160 patients enrolled in BriaCell's pivotal Phase 3 study in metastatic breast cancer (MBC)Enrollment exceeding expectations with strong clinical site and patient interestTopline interim data readout expected in 1H2026 Phase 3 combination regimen continues under FDA Fast Track designation PHILADELPHIA and VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 clinical study has screened over 230 and enrolled over 160 patient
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp
The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023. "As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive
SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)